Biotest is a global company that supplies plasma protein products and biotherapeutic drugs. Their products are primarily used in the therapeutic areas of clinical immunology, haematology and intensive care medicine. For patients with serious and often chronic diseases Biotest provides targeted treatment, which generally enable them to lead almost normal lives.
The company starts from pre-clinical and clinical development to manufacturing and global marketing. Research, development and production are carried out at their main headquarters in Germany and the USA. In addition to the company headquarters in Dreieich (near Frankfurt, Germany) and Biotest Pharmaceuticals Corp. in Boca Raton, Florida, USA, Biotest has subsidiaries and sales companies in seven European countries including France, Great Britain, Italy, Austria, Switzerland, Hungary, Spain, as well a Latin American affiliate in Brazil.
Contact
Biotest France SAS
45/47 rue d’Hauteville
75010 – Paris
Tel : +33 1 84 17 56 20
Biotest France’s Olivier Samama discusses their recent re-entry into France, their focus on homecare treatment, and their expertise in fractionation and plasma derived products. What are the objectives and goals…
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
See our Cookie Privacy Policy Here
